Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Comfort Systems USA Inc (FIX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Comfort Systems USA Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.99 (market cap $4.49B), while Comfort Systems USA Inc trades at $1,690 (market cap $59.26B). The key difference: Comfort Systems USA Inc is far larger — about 13.2× ACADIA Pharmaceuticals Inc.'s market cap, and Comfort Systems USA Inc pays a 0.15% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | FIX | |
|---|---|---|
Market Cap | $4.49B | $59.26B |
Sector | Health | Technology |
52-Week High | $28.06 | $2.07K |
52-Week Low | $20.06 | $527.42 |
Enterprise Value | $3.69B | $58.55B |
Dividend Yield | — | 0.15% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Comfort Systems USA (FIX) trades at $1,793.03, up 2.97% with strong earnings momentum as Q1 2026 EPS of $10.51 beat expectations of $6.81. The stock shows bearish technical signals but maintains robust fundamentals with 2025 revenue of $9.10B and net income of $1.02B. Recent news highlights leadership transitions and data center cooling demand driving growth.
Outlook remains positive with analyst consensus price target of $2,080 representing 16% upside potential. Key risks include execution challenges from record backlog and competitive pressures in HVAC infrastructure. The company's strong cash flow generation supports dividend payments and strategic acquisitions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Comfort Systems USA Inc
Comfort Systems USA is a premier provider of mechanical and electrical contracting services. It specializes in HVAC, plumbing, and energy management solutions for commercial and industrial facilities.
Read more on FIX →
